Challenges and Considerations of Preclinical Development for IPSC-Based Myogenic Cell Therapy

Overview

Journal Cells

Publisher MDPI

Specialties Biochemistry
Biophysics
Cell Biology
Molecular Biology

Date 2024 Apr 12

PMID 38607035

Authors

Congshan Sun

Carlo Serra

Brianna Harley Kalicharan

Jeffrey Harding

Mahendra Rao

Affiliations

Soon will be listed here.

Abstract

Cell therapies derived from induced pluripotent stem cells (iPSCs) offer a promising avenue in the field of regenerative medicine due to iPSCs' expandability, immune compatibility, and pluripotent potential. An increasing number of preclinical and clinical trials have been carried out, exploring the application of iPSC-based therapies for challenging diseases, such as muscular dystrophies. The unique syncytial nature of skeletal muscle allows stem/progenitor cells to integrate, forming new myonuclei and restoring the expression of genes affected by myopathies. This characteristic makes genome-editing techniques especially attractive in these therapies. With genetic modification and iPSC lineage specification methodologies, immune-compatible healthy iPSC-derived muscle cells can be manufactured to reverse the progression of muscle diseases or facilitate tissue regeneration. Despite this exciting advancement, much of the development of iPSC-based therapies for muscle diseases and tissue regeneration is limited to academic settings, with no successful clinical translation reported. The unknown differentiation process in vivo, potential tumorigenicity, and epigenetic abnormality of transplanted cells are preventing their clinical application. In this review, we give an overview on preclinical development of iPSC-derived myogenic cell transplantation therapies including processes related to iPSC-derived myogenic cells such as differentiation, scaling-up, delivery, and cGMP compliance. And we discuss the potential challenges of each step of clinical translation. Additionally, preclinical model systems for testing myogenic cells intended for clinical applications are described.

Citing Articles

Multitasking muscle: engineering iPSC-derived myogenic progenitors to do more.

Hamer M, Rossi F Front Cell Dev Biol. 2025; 12:1526635.

PMID: 39911186 PMC: 11794491. DOI: 10.3389/fcell.2024.1526635.

Advancements and challenges in stem cell transplantation for regenerative medicine.

Wei L, Yan W, Shah W, Zhang Z, Wang M, Liu B Heliyon. 2024; 10(16):e35836.

PMID: 39247380 PMC: 11379611. DOI: 10.1016/j.heliyon.2024.e35836.

References

Gabriels J, Beckers M, Ding H, De Vriese A, Plaisance S, van der Maarel S . Nucleotide sequence of the partially deleted D4Z4 locus in a patient with FSHD identifies a putative gene within each 3.3 kb element. Gene. 1999; 236(1):25-32. DOI: 10.1016/s0378-1119(99)00267-x. View

Hicks M, Hiserodt J, Paras K, Fujiwara W, Eskin A, Jan M . ERBB3 and NGFR mark a distinct skeletal muscle progenitor cell in human development and hPSCs. Nat Cell Biol. 2017; 20(1):46-57. PMC: 5962356. DOI: 10.1038/s41556-017-0010-2. View

Rezaie J, Feghhi M, Etemadi T . A review on exosomes application in clinical trials: perspective, questions, and challenges. Cell Commun Signal. 2022; 20(1):145. PMC: 9483361. DOI: 10.1186/s12964-022-00959-4. View

Araki E, Nakamura K, Nakao K, Kameya S, Kobayashi O, Nonaka I . Targeted disruption of exon 52 in the mouse dystrophin gene induced muscle degeneration similar to that observed in Duchenne muscular dystrophy. Biochem Biophys Res Commun. 1997; 238(2):492-7. DOI: 10.1006/bbrc.1997.7328. View

Trollet C, Anvar S, Venema A, Hargreaves I, Foster K, Vignaud A . Molecular and phenotypic characterization of a mouse model of oculopharyngeal muscular dystrophy reveals severe muscular atrophy restricted to fast glycolytic fibres. Hum Mol Genet. 2010; 19(11):2191-207. DOI: 10.1093/hmg/ddq098. View

Grady R, Teng H, Nichol M, Cunningham J, WILKINSON R, Sanes J . Skeletal and cardiac myopathies in mice lacking utrophin and dystrophin: a model for Duchenne muscular dystrophy. Cell. 1997; 90(4):729-38. DOI: 10.1016/s0092-8674(00)80533-4. View

Weller A, Magliato S, Bell K, Rosenberg N . Spontaneous myopathy in the SJL/J mouse: pathology and strength loss. Muscle Nerve. 1997; 20(1):72-82. DOI: 10.1002/(sici)1097-4598(199701)20:1<72::aid-mus10>3.0.co;2-3. View

Wang Z, Cheung D, Zhou Y, Han C, Fennelly C, Criswell T . An in vitro culture system that supports robust expansion and maintenance of in vivo engraftment capabilities for myogenic progenitor cells from adult mice. Biores Open Access. 2014; 3(3):79-87. PMC: 4048971. DOI: 10.1089/biores.2014.0007. View

Cohen P, Luquet E, Pletenka J, Leonard A, Warter E, Gurchenkov B . Engineering 3D micro-compartments for highly efficient and scale-independent expansion of human pluripotent stem cells in bioreactors. Biomaterials. 2023; 295:122033. DOI: 10.1016/j.biomaterials.2023.122033. View

10.

Davies J, Wang L, Garcia-Oroz L, Cook L, Vacher C, ODonovan D . Doxycycline attenuates and delays toxicity of the oculopharyngeal muscular dystrophy mutation in transgenic mice. Nat Med. 2005; 11(6):672-7. DOI: 10.1038/nm1242. View

11.

Magli A, Baik J, Mills L, Kwak I, Dillon B, Gonzalez R . Time-dependent Pax3-mediated chromatin remodeling and cooperation with Six4 and Tead2 specify the skeletal myogenic lineage in developing mesoderm. PLoS Biol. 2019; 17(2):e3000153. PMC: 6390996. DOI: 10.1371/journal.pbio.3000153. View

12.

Richard I, Roudaut C, Marchand S, Baghdiguian S, Herasse M, Stockholm D . Loss of calpain 3 proteolytic activity leads to muscular dystrophy and to apoptosis-associated IkappaBalpha/nuclear factor kappaB pathway perturbation in mice. J Cell Biol. 2001; 151(7):1583-90. PMC: 2150676. DOI: 10.1083/jcb.151.7.1583. View

13.

Liu X, Nefzger C, Rossello F, Chen J, Knaupp A, Firas J . Comprehensive characterization of distinct states of human naive pluripotency generated by reprogramming. Nat Methods. 2017; 14(11):1055-1062. DOI: 10.1038/nmeth.4436. View

14.

Gilbert R, Nalbantoglu J, Petrof B, Ebihara S, Guibinga G, Tinsley J . Adenovirus-mediated utrophin gene transfer mitigates the dystrophic phenotype of mdx mouse muscles. Hum Gene Ther. 1999; 10(8):1299-310. DOI: 10.1089/10430349950017987. View

15.

Casas-Mollano J, Zinselmeier M, Erickson S, Smanski M . CRISPR-Cas Activators for Engineering Gene Expression in Higher Eukaryotes. CRISPR J. 2020; 3(5):350-364. PMC: 7580621. DOI: 10.1089/crispr.2020.0064. View

16.

Xi H, Langerman J, Sabri S, Chien P, Young C, Younesi S . A Human Skeletal Muscle Atlas Identifies the Trajectories of Stem and Progenitor Cells across Development and from Human Pluripotent Stem Cells. Cell Stem Cell. 2020; 27(1):181-185. PMC: 9012334. DOI: 10.1016/j.stem.2020.06.006. View

17.

Faustino Martins J, Fischer C, Urzi A, Vidal R, Kunz S, Ruffault P . Self-Organizing 3D Human Trunk Neuromuscular Organoids. Cell Stem Cell. 2020; 27(3):498. DOI: 10.1016/j.stem.2020.08.011. View

18.

Chen Y, Zheng Y, Kang Y, Yang W, Niu Y, Guo X . Functional disruption of the dystrophin gene in rhesus monkey using CRISPR/Cas9. Hum Mol Genet. 2015; 24(13):3764-74. PMC: 5007610. DOI: 10.1093/hmg/ddv120. View

19.

Karpati G, Ajdukovic D, Arnold D, Gledhill R, Guttmann R, Holland P . Myoblast transfer in Duchenne muscular dystrophy. Ann Neurol. 1993; 34(1):8-17. DOI: 10.1002/ana.410340105. View

20.

Choi S, Ferrari G, Moyle L, Mackinlay K, Naouar N, Jalal S . Assessing and enhancing migration of human myogenic progenitors using directed iPS cell differentiation and advanced tissue modelling. EMBO Mol Med. 2022; 14(10):e14526. PMC: 9549733. DOI: 10.15252/emmm.202114526. View